Other substances

Streptomycin

An aminoglycoside antibiotic.

Phase of research

Potential treatment - theoretical effect

How it helps

Antiviral

Drug status

Used to treat other disease

1
 Supporting references
0
 Contradictory references
5
 AI-suggested references
0
 Clinical trials

General information

Streptomycin on PubChem

Marketed as

STREPTOMYCIN SULFATE

 

Structure image - Streptomycin

C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O

Supporting references

Link Tested on Impact factor Notes Publication date
In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19
Spike protein Small molecule In silico 		in silico 2.64

Predicted to block SARS-CoV-2 spike protein interaction with the host cell.

 Jul/01/2020

AI-suggested references

Link Publication date
Mesenchymal stromal cell delivery as a potential therapeutic strategy against COVID-19: Promising evidence from in vitro results
Apr/19/2022
Aminoglycosides as potential inhibitors of SARS-CoV-2 main protease: an in silico drug repurposing study on FDA-approved antiviral and anti-infection agents.
Feb/09/2021
Synthesis, anti-bacterial evaluation, DFT study and molecular docking as a potential 3-chymotrypsin-like protease (3CLpro) of SARS-CoV-2 inhibitors of a novel Schiff bases.
Oct/17/2020
Fast Identification of Possible Drug Treatment of Coronavirus Disease-19 (COVID-19) through Computational Drug Repurposing Study
Mar/25/2022
In silico screening of known small molecules to bind ACE2 specific RBD on Spike glycoprotein of SARS-CoV-2 for repurposing against COVID-19.
Jul/01/2020
Export (.csv)